Phage display technology: A tool to explore the diversity of inhibitors to blood coagulation factor VIII

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 2, 2000, Pages 143-150

  Voorberg, Jan ^a,b   Van Den Brink, Edward N ^a,b  

^a CENTRAL LABORATORY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Factor VIII; Factor VIII inhibitors; Hemophilia; Phage display; scFv

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; COMPLEMENTARY DNA; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; BIODIVERSITY; EPITOPE MAPPING; HEMOPHILIA A; HUMAN; MOLECULAR RECOGNITION; PHAGE DISPLAY; PRIORITY JOURNAL; REVIEW; TECHNOLOGY;

EID: 0033923626     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9816     Document Type: Review

References (37)

1. 1. Bidwell E, Denson KW, Dike GW. Antibody nature of the inhibitor to antihemophilic globulin (factor 8). Nature 1966;210: 746-747
2. 2. Hoyer LW. Hemophilia A. N Engl J Med 1994;330:38-47
3. 3. Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with an inhibitor. Blood 1998;92:416-506
4. 4. Davies J, Van den Brink EN, Baglin TP, et al. Primary structure of the variable domains of factor VIII antibodies obtained from inhibitor patient B cell RNA by V gene phage display technology. Thromb Haemost 1997;suppl:575A. Abstract
5. 5. Van den Brink EN, Turenhout EAM, Davies J, et al. VH domains of human inhibitors directed towards the factor VIII light chain contain an unusually large CDR3. Haemophilia 1998;4:230A. Abstract
6. 6. Van den Brink EN, Turenhout EAM, Davies J, et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood 2000;95:558-563
7. 7. Fulcher CA, DeGraaf Mahoney S, Roberts JR, et al. Localization of human factor VIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985;82:7728-7732
8. 8. Scandella D, DeGraaf Mahoney S, Mattingly M, et al. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci USA 1988;85:6152-6156
9. 9. Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995;86:1811-1819
10. 10. Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995;270:14505-14509
11. 11. Lubin IM, Healey JF, Barrow RT, et al. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J Biol Chem 1997;272:30191-30195
12. 12. Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998;92: 3701-3709
13. 13. Villoutreux BO, Bucher P, Hoffmann K, et al. Molecular models for the two discoidin domains of human blood coagulation factor V. J Molecular Models 1998;4:268-275
14. 14. Pellerquer J-L, Gate AJ, Griffin JH, et al. Homology models of the C domains of blood coagulation factors V and VIII: A proposed membrane binding mode for FV and FVIII C2 domains. Blood Cells Mol Dis 1998;15:448-461
15. 15. McMullen BA, Fujikawa K, Davie EW, et al. Locations of disulfide bonds and free cysteines in the heavy and light chain of recombinant human factor VIII (antihemophilic factor A). Protein Sci 1995;4:740-746
16. 16. Pratt KP, Shen BW, Fujikawa K, et al. Structure of the C2 of human factor VIII at 1.5 Å resolution. Nature 1999;402:439-442
17. 17. Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood 1993;82:1767-1775
18. 18. Fijnvandraat K, Celie PHN, Turenhout EAM, et al. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood 1998;91:2347-2352
19. 19. Zhong D, Saenko EL, Shima M, et al. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998;92:136-142
20. 20. Lenting PJ, Van de Loo J-WP, Donath M-JSH, et al. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996;271:1935-1940
21. 21. Prescott R, Nakai H, Saenko EL, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate study groups. Blood 1997;89:3663-3671
22. 22. Foster PA, Fulcher CA, Houghten RA, et al. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest 1988;82:123-128
23. 23. Tonegawa S. Somatic generation of antibody diversity. Nature 1983;302:575-581
24. 24. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996;381:751-758
25. 25. Stavnezer J. Immunoglobulin class switching. Curr Opin Immunol 1996;8:199-205
26. 26. Hoyer LW, Gawryl MS, De la Fuente B. Immunochemical characterization of factor VIII inhibitors. In: Hoyer LW, ed. Factor VIII Inhibitors, Progress in Clinical and Biological Research, Vol. 150 New York: Liss; 1988:73-85
27. 27. Fulcher CA, De Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987;69:1475-1480
28. 28. Aalberse RC, van der Gaag R, van Leeuwen J. Serological aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4 restricted response. J Immunol 1983;130:722-726
29. 29. Cook GP, Tomlinson IM. The human immunoglobulin VH repertoire. Immunol Today 1995;16:237-242
30. 30. Williams SC, Winter G. Cloning and sequencing of human immunoglobulin Vλ gene segments. Eur J Immunol 1993;23: 1456-1461
31. 31. Cox JPL, Tomlinson IM, Winter G. A directory of human germline Vκ segments reveals a strong bias in their usage. Eur J Immunol 1994;24:827-836
32. 32. Matsuda F, Ishii K, Bourvagnet P, et al. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J Exp Med 1998;188:2151-2162
33. 33. Marks JD, Hoogenboom HR, Bonnert TP, et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991;222:581-597
34. 34. Griffin HM, Ouwehand WH. A human monoclonal antibody specific for the leucine-33 (p1A1, HPA-Ia) form of platelet glycoprotein IIIa from a V gene phage display library. Blood 1995; 86:4430-4436
35. 35. De Wildt RMT, Hoet RMA, Van Venrooij WJ, et al. Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J Mol Biol 1999;285: 895-901
36. 36. Ohlin M, Borrebaeck CA. Characteristics of human antibody repertoires following active immune responses in vivo. Mol Immunol 1996;33:583-592
37. 37. Kabat EA, Wu TT, Parry HM, Gottesman KE, Foeller C. Sequences of Immunological Interest, ed 5. Bethesda, MD: U.S. Department of Health and Human Services, 1991